Fred Hutchinson Cancer Research Center's Cord Blood Program was launched in 2006. Since then, we have performed more than 300 transplants in patients with malignant and non-malignant diseases who range in age from less than 1 year to 71 years.
The laboratory and clinical research components of the Cord Blood Program work together and in collaboration with our colleagues across Fred Hutch to improve outcomes for cord blood transplant recipients. This collaboration emphasizes understanding of how cord blood cells engraft (take hold in a patient), improving conditioning regimens, and developing standards of care for infection prevention. Our work has explored conventional as well as innovative approaches to achieving these goals. Outcomes for our patients reflect this effort, with survival rates equivalent to patients receiving unrelated donor bone marrow or peripheral blood hematopoietic cell transplants.
For information about how to enroll in open clinical trials, please visit the Seattle Cancer Care Alliance.